CN104434788A - 一种阿替洛尔注射液的制备方法 - Google Patents
一种阿替洛尔注射液的制备方法 Download PDFInfo
- Publication number
- CN104434788A CN104434788A CN201410817384.6A CN201410817384A CN104434788A CN 104434788 A CN104434788 A CN 104434788A CN 201410817384 A CN201410817384 A CN 201410817384A CN 104434788 A CN104434788 A CN 104434788A
- Authority
- CN
- China
- Prior art keywords
- atenolol
- sodium
- injection
- inj
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 title claims abstract description 73
- 229960002274 atenolol Drugs 0.000 title claims abstract description 73
- 238000002347 injection Methods 0.000 title claims abstract description 26
- 239000007924 injection Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000243 solution Substances 0.000 claims abstract description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 23
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 19
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 19
- 239000011780 sodium chloride Substances 0.000 claims abstract description 19
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 6
- 230000003204 osmotic effect Effects 0.000 claims abstract description 5
- 239000007853 buffer solution Substances 0.000 claims abstract description 4
- 239000003610 charcoal Substances 0.000 claims description 29
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 22
- 235000019800 disodium phosphate Nutrition 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 13
- 239000008215 water for injection Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 239000010936 titanium Substances 0.000 claims description 9
- 229910052719 titanium Inorganic materials 0.000 claims description 9
- -1 polypropylene Polymers 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000000536 complexating effect Effects 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 239000013618 particulate matter Substances 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 51
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 239000002510 pyrogen Substances 0.000 abstract description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
- 239000008139 complexing agent Substances 0.000 abstract 1
- 229940037001 sodium edetate Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 46
- 229940090044 injection Drugs 0.000 description 14
- 238000012360 testing method Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 239000005388 borosilicate glass Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000013112 stability test Methods 0.000 description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940116866 metoprolol injection Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
原辅料名称 | 使用量 |
阿替洛尔 | 4.5-5.5g |
磷酸二氢钠 | 0.12-12.0g |
依地酸钠 | 1.0-5.0g |
氯化钠 | 0-90.0g |
0.1mol/L磷酸氢二钠 | 1-50mL |
1,2-丙二醇 | 1000-3500mL |
注射用水 | 定容至10L |
共制成 | 1000支 |
原辅料名称 | 使用量 |
阿替洛尔 | 5.0g |
氯化钠 | 90g |
依地酸钠 | 5.0g |
磷酸二氢钠 | 12.0g |
0.1mol/l磷酸氢二钠 | 20ml |
1,2-丙二醇 | 3500ml |
注射用水 | 定容至10L |
共制成 | 1000支 |
原辅料名称 | 使用量 |
阿替洛尔 | 5.0g |
氯化钠 | 75g |
依地酸钠 | 3.0g |
磷酸二氢钠 | 6.0g |
0.1mol/l磷酸氢二钠 | 8ml |
1,2-丙二醇 | 2000ml |
注射用水 | 定容至10L |
共制成 | 1000支 |
原辅料名称 | 使用量 |
阿替洛尔 | 5.0g |
氯化钠 | 45g |
依地酸钠 | 1.5g |
磷酸二氢钠 | 1.2g |
0.1mol/l磷酸氢二钠 | 3ml |
1,2-丙二醇 | 2500ml |
注射用水 | 定容至10L |
共制成 | 1000支 |
原辅料名称 | 使用量 |
阿替洛尔 | 5.0g |
氯化钠 | 90g |
依地酸钠 | 3.0g |
磷酸二氢钠 | 0.12g |
0.1mol/l磷酸氢二钠 | 1.2ml |
1,2-丙二醇 | 3000ml |
注射用水 | 定容至10L |
共制成 | 1000支 |
原辅料名称 | 使用量 |
阿替洛尔 | 5.0g |
氯化钠 | 90g |
依地酸钠 | 4.0g |
磷酸二氢钠 | 8.0g |
0.1mol/l磷酸氢二钠 | 5ml |
1,2-丙二醇 | 2000ml |
注射用水 | 定容至10L |
共制成 | 1000支 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410817384.6A CN104434788B (zh) | 2014-12-24 | 2014-12-24 | 一种阿替洛尔注射液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410817384.6A CN104434788B (zh) | 2014-12-24 | 2014-12-24 | 一种阿替洛尔注射液的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104434788A true CN104434788A (zh) | 2015-03-25 |
CN104434788B CN104434788B (zh) | 2017-11-03 |
Family
ID=52882058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410817384.6A Active CN104434788B (zh) | 2014-12-24 | 2014-12-24 | 一种阿替洛尔注射液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104434788B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168122A (zh) * | 2015-09-24 | 2015-12-23 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液及其制备工艺 |
CN108888593A (zh) * | 2018-06-27 | 2018-11-27 | 济南康和医药科技有限公司 | 一种阿替洛尔注射液及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099699A1 (en) * | 2004-04-07 | 2005-10-27 | Sepracor Inc. | Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension |
CN102240262A (zh) * | 2010-05-14 | 2011-11-16 | 山东方明药业股份有限公司 | 盐酸地尔硫卓注射液及其制备方法 |
-
2014
- 2014-12-24 CN CN201410817384.6A patent/CN104434788B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099699A1 (en) * | 2004-04-07 | 2005-10-27 | Sepracor Inc. | Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension |
CN102240262A (zh) * | 2010-05-14 | 2011-11-16 | 山东方明药业股份有限公司 | 盐酸地尔硫卓注射液及其制备方法 |
Non-Patent Citations (3)
Title |
---|
刘朝阳,等: "阿替洛尔注射液对血管刺激、溶血和过敏的实验研究", 《中国新药与临床杂志》 * |
惠红,等: "活性炭在注射液配制中对主药含量的影响", 《现代医药卫生》 * |
无: "阿替洛尔注射液", 《百度百科:HTTP://BAIKE.BAIDU.COM/HISTORY/阿替洛尔注射液/61586350》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168122A (zh) * | 2015-09-24 | 2015-12-23 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液及其制备工艺 |
CN105168122B (zh) * | 2015-09-24 | 2018-11-27 | 辰欣药业股份有限公司 | 一种盐酸右美托咪定注射液及其制备工艺 |
CN108888593A (zh) * | 2018-06-27 | 2018-11-27 | 济南康和医药科技有限公司 | 一种阿替洛尔注射液及其制备方法 |
CN108888593B (zh) * | 2018-06-27 | 2021-09-21 | 济南康和医药科技有限公司 | 一种阿替洛尔注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104434788B (zh) | 2017-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Streicher et al. | Syndromes of toluene sniffing in adults | |
Hiller et al. | Safety of high volume lipid emulsion infusion | |
Chan et al. | The effect of ageing on plasma pethidine concentration. | |
CN1170589C (zh) | ***和铁制剂在制备治疗风湿病的药物联合制剂中的用途 | |
CN102552294B (zh) | 一种注射用复方维生素冻干粉针剂组合物 | |
SHAFER et al. | Pharmacokinetic variability of midazolam infusions in critically ill patients | |
CN101836952A (zh) | 一种氨溴索注射剂及其制备方法 | |
CN102138919A (zh) | 铁叶绿酸钠用于促进红细胞生成的新用途 | |
CN103463565A (zh) | 一种莪术油注射液及其制备方法 | |
CN101254316B (zh) | 一种抗凝专用血滤置换液 | |
CN104434788A (zh) | 一种阿替洛尔注射液的制备方法 | |
CN102145164B (zh) | 一种更加稳定的iapp类似物注射剂 | |
CN104706655B (zh) | 注射用环磷腺苷葡胺粉针剂药物组合物和制法 | |
CN101836997B (zh) | 一种甘油与果糖组合物的制备方法 | |
CN102525909B (zh) | 盐酸戊乙奎醚注射液的制备方法 | |
CN116157119A (zh) | 一种ARNi与钙离子拮抗剂的药物组合物与应用 | |
CN112569210B (zh) | 一种吸入用马昔腾坦溶液及其制备方法 | |
CN101450075A (zh) | 羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 | |
CN110214019B (zh) | 培化西海马肽的药物组合物及其制备方法 | |
CN103202805B (zh) | 一种含有长春西汀的注射用药物组合物及其制备方法 | |
CN107334729B (zh) | 一种单唾液酸四己糖神经节苷脂钠口服液及其用途 | |
Garrett et al. | Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration | |
CN101822690A (zh) | 一种右旋糖酐40与乳酸钠林格氏液组合物及制备方法 | |
Yue et al. | Population pharmacokinetic and pharmacodynamic modeling of acetazolamide in peritoneal dialysis patients and healthy volunteers | |
Roberts et al. | Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained‐release diltiazem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of atenolol injection Effective date of registration: 20180508 Granted publication date: 20171103 Pledgee: Shandong Tengzhou rural commercial bank Limited by Share Ltd. SME branch Pledgor: SHANDONG YIKANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018370000084 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200521 Granted publication date: 20171103 Pledgee: Shandong Tengzhou rural commercial bank Limited by Share Ltd. SME branch Pledgor: SHANDONG YIKANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018370000084 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of atenolol injection Effective date of registration: 20220330 Granted publication date: 20171103 Pledgee: Tengzhou sub branch of Postal Savings Bank of China Ltd. Pledgor: SHANDONG YIKANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980003504 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231213 Granted publication date: 20171103 Pledgee: Tengzhou sub branch of Postal Savings Bank of China Ltd. Pledgor: SHANDONG YIKANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980003504 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method for atenolol injection Effective date of registration: 20231215 Granted publication date: 20171103 Pledgee: Tengzhou sub branch of Postal Savings Bank of China Ltd. Pledgor: SHANDONG YIKANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980071838 |